204 related articles for article (PubMed ID: 24323313)
1. Peptide receptor radionuclide therapy for aggressive atypical pituitary adenoma/carcinoma: variable clinical response in preliminary evaluation.
Maclean J; Aldridge M; Bomanji J; Short S; Fersht N
Pituitary; 2014 Dec; 17(6):530-8. PubMed ID: 24323313
[TBL] [Abstract][Full Text] [Related]
2. The use of (68)Ga DOTATATE PET/CT for diagnostic assessment and monitoring of (177)Lu DOTATATE therapy in pituitary carcinoma.
Novruzov F; Aliyev JA; Jaunmuktane Z; Bomanji JB; Kayani I
Clin Nucl Med; 2015 Jan; 40(1):47-9. PubMed ID: 25275413
[TBL] [Abstract][Full Text] [Related]
3. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
4. Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience.
Delpassand ES; Samarghandi A; Zamanian S; Wolin EM; Hamiditabar M; Espenan GD; Erion JL; O'Dorisio TM; Kvols LK; Simon J; Wolfangel R; Camp A; Krenning EP; Mojtahedi A
Pancreas; 2014 May; 43(4):518-25. PubMed ID: 24632546
[TBL] [Abstract][Full Text] [Related]
5. Growth hormone-secreting macroadenoma of the pituitary gland successfully treated with the radiolabeled somatostatin analog (90)Y-DOTATATE: case report.
Waligórska-Stachura J; Gut P; Sawicka-Gutaj N; Liebert W; Gryczyńska M; Baszko-Błaszyk D; Blanco-Gangoo AR; Ruchała M
J Neurosurg; 2016 Aug; 125(2):346-9. PubMed ID: 26636388
[TBL] [Abstract][Full Text] [Related]
6. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
[No Abstract] [Full Text] [Related]
7. Cardiac Toxicity in a Patient Receiving Peptide Receptor Radionuclide Therapy.
Hendifar AE; Delpassand ES; Kittleson MM; Tuli R
Pancreas; 2018 Sep; 47(8):e55-e56. PubMed ID: 30113434
[No Abstract] [Full Text] [Related]
8. Use of
Oliván-Sasot P; Falgás-Lacueva M; García-Sánchez J; Vera-Pinto V; Olivas-Arroyo C; Bello-Arques P
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):116-119. PubMed ID: 27793633
[TBL] [Abstract][Full Text] [Related]
9.
Hervás I; Bello P; Falgas M; Del Olmo MI; Torres I; Olivas C; Vera V; Oliván P; Yepes AM
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):91-98. PubMed ID: 27889527
[TBL] [Abstract][Full Text] [Related]
10.
Parghane RV; Talole S; Basu S
Ann Nucl Med; 2021 Jan; 35(1):92-101. PubMed ID: 33135123
[TBL] [Abstract][Full Text] [Related]
11. The Bad Berka dose protocol: comparative results of dosimetry in peptide receptor radionuclide therapy using (177)Lu-DOTATATE, (177)Lu-DOTANOC, and (177)Lu-DOTATOC.
Schuchardt C; Kulkarni HR; Prasad V; Zachert C; Müller D; Baum RP
Recent Results Cancer Res; 2013; 194():519-36. PubMed ID: 22918780
[TBL] [Abstract][Full Text] [Related]
12. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study.
Braat AJAT; Bruijnen RCG; van Rooij R; Braat MNGJA; Wessels FJ; van Leeuwaarde RS; van Treijen MJC; de Herder WW; Hofland J; Tesselaar MET; de Jong HWAM; Lam MGEH
Lancet Oncol; 2020 Apr; 21(4):561-570. PubMed ID: 32112737
[TBL] [Abstract][Full Text] [Related]
13. Safety, Pharmacokinetics, and Dosimetry of a Long-Acting Radiolabeled Somatostatin Analog
Zhang J; Wang H; Jacobson O; Cheng Y; Niu G; Li F; Bai C; Zhu Z; Chen X
J Nucl Med; 2018 Nov; 59(11):1699-1705. PubMed ID: 29653971
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
15. Radionuclide Therapy for Neuroendocrine Tumors.
Cives M; Strosberg J
Curr Oncol Rep; 2017 Feb; 19(2):9. PubMed ID: 28220446
[TBL] [Abstract][Full Text] [Related]
16. Polish experience in Peptide receptor radionuclide therapy.
Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for peptide receptor radionuclide therapy in medullary thyroid cancer?
Vaisman F; Rosado de Castro PH; Lopes FP; Kendler DB; Pessoa CH; Bulzico DA; de Carvalho Leal D; Vilhena B; Vaisman M; Carneiro M; Corbo R
Clin Nucl Med; 2015 Feb; 40(2):123-7. PubMed ID: 25546220
[TBL] [Abstract][Full Text] [Related]
18. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
[TBL] [Abstract][Full Text] [Related]
19. Peptide receptor radionuclide therapy with (177)Lu labeled somatostatin analogs DOTATATE and DOTATOC: contrasting renal dosimetry in the same patient.
Kulkarni HR; Schuchardt C; Baum RP
Recent Results Cancer Res; 2013; 194():551-9. PubMed ID: 22918782
[TBL] [Abstract][Full Text] [Related]
20. Peptide receptor radionuclide therapy with (177)Lu-DOTATATE in advanced bronchial carcinoids: prognostic role of thyroid transcription factor 1 and (18)F-FDG PET.
Ianniello A; Sansovini M; Severi S; Nicolini S; Grana CM; Massri K; Bongiovanni A; Antonuzzo L; Di Iorio V; Sarnelli A; Caroli P; Monti M; Scarpi E; Paganelli G
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1040-6. PubMed ID: 26611427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
